Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma; Ocular Hypertension
Intervention: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops (Drug); latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s):
Medical Affairs, Study Director, Affiliation: Allergan
Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost
0. 005%, and in need of additional IOP lowering will be randomized to receive either
brimonidine 0. 1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost
0. 005%
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Primary outcome: IOP
Secondary outcome: Tolerability
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Glaucoma or ocular hypertension in both eyes
- Currently being treated with latanoprost 0. 005% QD
- IOP greater than or equal to 18mm Hg on latanoprost 0. 005%
- Best-corrected VA of 20/200 or better in each eye
- Visual field within 6 months of study entry
Exclusion Criteria:
- Secondary glaucoma
- Active intraocular inflammation or macular edema
- Intraocular surgery or laser surgery within the past 3 months
Locations and Contacts
Atlanta, Georgia, United States
Additional Information
Starting date: July 2006
Last updated: December 26, 2007
|
